The Catalyst

Most Recent Posts

01.11.12 | By Kate Connors

Today I'm pleased to introduce to Catalyst readers PhRMA's new vice president of scientific affairs, Dr. Salvatore Alesci. Dr. Alesci has worked in research at the government level, for the National Institutes of Health, as well as for several biopharmaceutical research companies. Today, I sat down with Dr. Alesci to ask him a few questions about his experiences and his thoughts about the future of R&D.

How did you get into the field of biopharmaceutical research and development?

01.10.12 | By Jeff Trewhitt

A steady stream of state legislatures is coming back into session throughout the month, and considering that most states have budget shortfalls, Medicaid is likely to emerge as a popular target for cuts.

01.10.12 | By Greg Lopes

Yesterday, the government released its annual report on how much we're spending as a country on health care goods and services. Formally known as the National Health Expenditure Accounts, the government research shows a continued rate of historically low spending growth for retail prescription medicines.

01.09.12 | By Kate Connors

I hate cancer. I have too many friends and loved ones battling this awful disease right now - though, admittedly, even one is one too many.

Fortunately, as of very recently, one of those friends is winning her fight.

01.09.12 | By Jennifer Wall

It is worth checking out an interesting blog piece that ran in The Washington Post over the weekend about the government funding military innovation. Oftentimes, people mistakenly believe that the government also funds the majority of biopharmaceutical innovation, but this couldn't be further from the truth.

01.06.12 | By Greg Lopes

An article in yesterday's Wall Street Journal (subscription required) presents some exciting news on the fight against HIV/AIDS. New research, to be published Wednesday in the journal Nature, shows that some investigational new vaccines may protect monkeys against a powerful strain of the virus.

01.05.12 | By Karl Uhlendorf

Evidence of recent progress in our collective fight against cancer continued yesterday with the American Cancer Society's annual report, Cancer Statistics, 2012. According to ACS, between 1990/1991 and 2008, overall death rates from cancer fell by approximately 23 percent in men and 15 percent in women - meaning that more than a million deaths from cancer were prevented.

01.05.12 | By Kate Connors

Associated Press reporter Linda Johnson wrote a great article this week (find it here on the Chicago Tribune's site) about medication adherence. I hate to say it's an exhaustive commentary on adherence, since that's a pretty big issue to cover, but she captures a lot - including, importantly, tips about programs, apps and resources to help patients adhere.

For example:

01.04.12

For some important perspective on some of challenges and questions we at PhRMA will be focusing on during 2012 and into the future, take a look at PhRMA President John Castellani's contribution to Chain Drug Review's annual "Pharmacy Outlook '12" issue.

01.03.12 | By Kate Connors

In case you haven't yet heard, FDA recently launched a blog, FDA Voice, as part of its recent Website redesign. Kicked off by a post from Commissioner Margaret Hamburg, the blog promises to "give you insights on some of the most pressing public health issues of the day."

12.21.11 | By Jenni Brewer
After a momentous year, Washington is readying itself for holiday vacation. There's no better indication than my traffic-free commute over the bridge - it was, dare I say, relaxing. I welcome the slower pace not just for the liberation from gridlock; it's a chance to reflect on the year. And on the biopharmaceutical industry front, it was 12 months of major medical advances.
12.15.11 | By Kate Connors
On the Pharmalot blog, Ed Silverman published an interesting op-ed by Brian Reid, a social media expert with WCG, about the lack of FDA guidance on social media.
12.15.11 | By Jeff Trewhitt
Here at PhRMA, I'm known as a bit of a road warrior. There's nothing I enjoy more than leaving Washington, D.C. in the rear view mirror to travel around the country on behalf of the biopharmaceutical research industry to meet with reporters, legislators, local business leaders and, sometimes, even university research officials. We've got a story to tell and as a hairy cell leukemia survivor saved by a chemotherapy and some powerful antibiotics, I'm happy to tell it.
12.14.11 | By Preet Bilinski
Hear from Dr. John Pottage, the chief scientific and medical officer for ViiV Healthcare, who has been in the battle against HIV/AIDS since before we even identified the disease. He discusses the improvements that new medicines and therapies have made for patients. But with a new infection occurring every nine and a half minutes, more needs to be done. America's biopharmaceutical companies agree and are continuing their fight against this epidemic with 88 medicines and vaccines in development for HIV/AIDS.
12.13.11 | By Kate Connors
In The Hill's CongressBlog, PhRMA President and CEO John J. Castellani had an op-ed today about how our federal efforts to stimulate economic growth will undoubtedly lack the momentum they need without a related emphasis on exports - and the biopharmaceutical sector, already a major generator of exports, can help. But we need support.

Pages